|
Commission Legal Brief: Gryl v. Shire Pharmaceuticals Group / June 21, 2002 (5343 words) |
 | The plaintiffs allege that defendants acquired options in Shire Pharmaceuticals Group PLC ("Shire") while the defendants were directors of Shire and then exercised some of their options and sold the resultingShire stock within six months of acquiring the options. |
| The plaintiffs further contend that the Shire Board's approval was deficient in that it did not state that it was for the purpose of exempting the transactions from Section 16(b). |
| Most notably, the plaintiffs point to a Shire board resolution from six weeks before the merger became effective, which states that "conditional upon completion of the Merger and admission of the Consideration Shares to the Official List, [the defendants] are hereby appointed as non-executive directors of the Company" (A785). |
| medications - Shire Pharmaceuticals (390 words) |
| Founded in 1986, Shire Pharmaceuticals Group plc is a rapidly growing international emerging pharmaceutical company with revenues for the full year 2002 of $1,037.3 million and an operating income of $327.038 million. |
| Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international emerging pharmaceutical company with a strategic focus on four therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI), oncology, and anti-infectives. |
| Shire's core strategy is based on research and development combined with in-licensing and a focus on key pharmaceutical markets. |
Feeds |
Contact